Clay Siegall on Innovative Treatment for Lymphoma

Cancer is one of the world’s primary medical problems today. At least one life in every family is lost to cancer. Various medical programs have been established seeking the cure for cancer. Although cancer is treatable at an early stage, the world still hopes to find a cure to save lives. Joe Biden’s visit to Seattle Genetics gave Puget Sound, cancer research company fame in the country. Seattle Genetics, the Bothell- based company is focused on enlarging its capacity for drug production. The Seattle cancer research center is trying out its new commercialized drug for cancer, Adcetris, in major cancer centers. Having been tested in more than fifty cancer research centers, Adcetris is hopefully the cure for lymphomas and other types of cancer.

Seattle Genetics is conducting a three-phase drug test on Adcetris, with the hope of curing the untreated cases of Hodgkin lymphoma. According to Siegall, the Hodgkin lymphoma test is the biggest trial test with the most significant impact on the company.

Seattle Genetics is a US based biotechnology company committed to developing, and implementing new innovative therapies and tests for cancer treatment. Seattle Genetics’ headquarters is geographically located in Bothell, Washington and is the industry leader in antibody –drug conjugates, the science behind antibodies developed to kill cancer cells. The antibodies are expected to spare none- targeted cells of the body while killing the cancer cells. Seattle Genetics focuses on providing patient care, teamwork, and individual excellence with the aim of fighting cancer and cancer-related diseases. Focused on expanding clinical opportunities of brentuximab vedotin, a drug developed for various lymphoma conditions, Seattle Genetics merged with Takeda Pharmaceutical Company. Seattle Genetics has full rights to brentuximab vedotin in Canada and the United States.

About Clay Siegall

Clay Siegall is the co- founder and president of Seattle Genetics. He serves as the chief executive officer and chairperson of the Seattle board of directors too. The trained scientist focuses on developing new cancer treatments and trials for various types of cancer. He is responsible for the leadership positions at Seattle Genetics focused on developing antidrug conjugates (ADCs). Clay Siegell’s leadership skills ranked Seattle Genetics one of the best in the world having entered partnerships with the likes of GlaxoSmithKline (GSK) and Pfizer. Dr. Siegall commits himself to innovations for various cancer treatments.